Carmen García-Mora

Suggest Changes
  • Citations Per Year
Learn More
e14525 Background: Sorafenib, an inhibitor of B-raf, VEGFR2, and PDGFR-beta, has activity against pancreatic cancer in pre-clinical models. Due to the radio-sensitization activity of S and G we(More)
  • 1